Takayuki Miki Selected Research

lucifer yellow

2/2009	Roles of Cx43-associated protein kinases in suppression of gap junction-mediated chemical coupling by ischemic preconditioning.
9/2007	Delta-opioid receptor activation before ischemia reduces gap junction permeability in ischemic myocardium by PKC-epsilon-mediated phosphorylation of connexin 43.
5/2006	MitoKATP channel activation suppresses gap junction permeability in the ischemic myocardium by an ERK-dependent mechanism.
1/2004	Protective role of gap junctions in preconditioning against myocardial infarction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takayuki Miki Research Topics

Disease

33	Infarction (Infarctions) 02/2022 - 01/2002
24	Ischemia 01/2018 - 07/2002
16	Myocardial Infarction 01/2020 - 01/2002
8	Type 2 Diabetes Mellitus (MODY) 01/2021 - 12/2009
7	Necrosis 01/2018 - 10/2003
6	Reperfusion Injury 01/2016 - 10/2003
4	Diabetes Mellitus 01/2022 - 10/2003
4	Neoplasms (Cancer) 01/2021 - 12/2019
4	Insulin Resistance 01/2021 - 11/2017
3	Left Ventricular Dysfunction 01/2021 - 02/2006
3	Heart Failure 01/2018 - 07/2009
3	Myocardial Ischemia (Ischemic Heart Diseases) 01/2018 - 10/2003
3	Ventricular Remodeling 04/2006 - 01/2002
2	Chronic Renal Insufficiency 02/2022 - 01/2016
2	Hyperglycemia 06/2021 - 01/2020
2	Ventricular Dysfunction 01/2021 - 10/2003
2	Hypertension (High Blood Pressure) 01/2021 - 10/2003
2	Acute Kidney Injury (Acute Renal Failure) 01/2020 - 12/2017
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 01/2017
2	Coronary Occlusion 01/2016 - 02/2006
2	Coronary Artery Disease (Coronary Atherosclerosis) 07/2009 - 10/2003
2	Myocardial Stunning (Stunned Myocardium) 02/2004 - 06/2003
2	No-Reflow Phenomenon 10/2003 - 10/2002
2	Hypercholesterolemia 10/2003 - 10/2002
2	Body Weight (Weight, Body) 06/2003 - 01/2002
1	Anemia 02/2022
1	COVID-19 01/2022
1	Infections 06/2021
1	Hypoglycemia (Reactive Hypoglycemia) 06/2021
1	Breast Neoplasms (Breast Cancer) 01/2021
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Coronary Stenosis (Coronary Artery Stenosis) 01/2021
1	Cardio-Renal Syndrome 07/2019

Drug/Important Bio-Agent (IBA)

9	salicylhydroxamic acid (SHAM)IBA 01/2018 - 01/2002
8	Erythropoietin FDA Link 12/2012 - 04/2006
7	Adenosine Triphosphate (ATP)IBA 01/2018 - 07/2002
6	Proteins (Proteins, Gene)FDA Link 01/2019 - 07/2002
6	Mitochondrial Permeability Transition PoreIBA 01/2018 - 11/2007
5	Glucose (Dextrose)FDA LinkGeneric 06/2021 - 03/2013
5	Glycogen Synthase Kinase 3 betaIBA 12/2009 - 08/2006
4	Leucine-2-Alanine Enkephalin (Enkephalin, Leucine 2 Alanine)IBA 06/2012 - 09/2006
4	lucifer yellowIBA 02/2009 - 01/2004
4	Protein Kinase C-epsilonIBA 02/2009 - 07/2002
4	Protein Kinase CIBA 02/2009 - 10/2002
3	Peptides (Polypeptides)IBA 01/2021 - 09/2007
3	empagliflozinIBA 01/2020 - 01/2018
3	Sodium-Glucose Transporter 2 InhibitorsIBA 07/2019 - 01/2018
3	Dihydrotachysterol (AT 10)IBA 01/2018 - 05/2006
3	Glycogen Synthase (Synthase I)IBA 01/2011 - 02/2009
3	Protein Kinases (Protein Kinase)IBA 12/2010 - 02/2009
3	Diazoxide (Hyperstat)FDA Link 11/2010 - 07/2002
3	Valsartan (Vals)FDA Link 01/2010 - 01/2002
3	delta Opioid Receptors (delta Opioid Receptor)IBA 01/2010 - 09/2006
3	Connexin 43 (Connexin43)IBA 02/2009 - 01/2004
3	Angiotensin IIIBA 04/2004 - 01/2002
3	Nicorandil (SG 75)IBA 10/2003 - 10/2002
2	Hemoglobins (Hemoglobin)IBA 02/2022 - 06/2021
2	Pharmaceutical PreparationsIBA 01/2021 - 02/2009
2	Galectin 3 (LGALS3)IBA 01/2021 - 03/2020
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 11/2016 - 10/2002
2	Cardiotonic Agents (Cardiac Stimulants)IBA 06/2012 - 11/2008
2	Phosphotransferases (Kinase)IBA 12/2010 - 07/2009
2	ATP Translocases Mitochondrial ADPIBA 11/2010 - 07/2009
2	SB 216763IBA 11/2010 - 08/2006
2	EnkephalinsIBA 01/2010 - 09/2007
2	Acetates (Acetic Acid Esters)FDA Link 01/2010 - 09/2007
2	Heptanol (1 Heptanol)IBA 09/2007 - 01/2004
2	2- (2- amino- 3- methoxyphenyl)- 4H- 1- benzopyran- 4- oneIBA 09/2006 - 05/2006
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 02/2006 - 12/2004
2	Macrophage Colony-Stimulating FactorIBA 02/2006 - 12/2004
2	Messenger RNA (mRNA)IBA 02/2006 - 12/2004
2	potassium bromideIBA 04/2004 - 07/2002
2	2- (2- (4- (4- nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonateIBA 06/2003 - 07/2002
2	mitochondrial K(ATP) channelIBA 02/2003 - 10/2002
1	HematinicsIBA 02/2022
1	PotassiumIBA 06/2021
1	Insulin (Novolin)FDA Link 06/2021
1	NitrogenIBA 06/2021
1	Urea (Carbamide)FDA LinkGeneric 06/2021
1	AMP Deaminase (Myoadenylate Deaminase)IBA 01/2021
1	LectinsIBA 01/2021
1	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2021
1	Phenylephrine (Neo-Synephrine)FDA LinkGeneric 01/2021
1	Adenine NucleotidesIBA 01/2021
1	Biological ProductsIBA 01/2021
1	HydrogelsIBA 01/2021
1	Galactose (Galactopyranose)FDA LinkGeneric 01/2021
1	LipidsIBA 01/2021
1	galactose-binding proteinIBA 03/2020
1	benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketoneIBA 12/2019
1	HDL CholesterolIBA 07/2019
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 07/2019
1	Triglycerides (Triacylglycerol)IBA 07/2019
1	CanagliflozinIBA 07/2019
1	SodiumIBA 07/2019
1	AntioxidantsIBA 01/2019

Therapy/Procedure

6	Therapeutics 02/2022 - 10/2002
4	Ligation 01/2018 - 05/2003
2	Glycemic Control 01/2022 - 08/2014
1	Blood Transfusion (Blood Transfusions) 02/2022